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Adoptive cell therapy with genetically engineered T-cells is providing a new approach to treat a 
variety of lymphomas, leukemias and solid tumors. For most cancer patients their T-cells, an 
important anti-tumor component of the immune system, become tolerant to tumor cell antigens. The 
inability of the immune system to respond to tumors has remained a major barrier to immune-
mediated anti-cancer therapies, but novel modifications to patients’ T-cells promise to overcome this 
problem. 
In adoptive T-cell therapy, patients’ T-cells are isolated, stimulated to proliferate, and engineered to 
express a chimeric antigen receptor (CAR). The CAR specifically recognizes a tumor antigen and is 
capable of signaling the T-cell to proliferate and mount a cytotoxic response against the tumor. 
A recent pilot study by Drs. Brian Till, Oliver Press and colleagues in the Clinical Research Division 
has combined recent advances in genetic engineering of T-cells with pre-transfer lymphodepletion to 
treat non-Hodgkin lymphoma patients. In this study, T-cells from three patients with relapsed 
indolent B-cell lymphomas were expanded and engineered to express a CAR recognizing CD20, a 
cell surface protein expressed on the patients’ B-lineage tumor cells. In addition, the intracellular 
portion of the CAR contained the CD28 and CD137 co-stimulatory domains, a maneuver that has 
recently been shown to enhance T-cell activity compared to earlier generations of T-cell therapies. 
The inclusion of multiple co-stimulatory domains increased T-cell expansion and cytokine 
production in vitro, and was expected to produce better anti-tumor responses in vivo. Prior to T-cell 
transfer, patients were treated with cyclophosphamide chemotherapy to cause lymphodepletion, with 
the goal of improving engraftment of the transferred T-cells. Patients were then followed for the 
presence of the modified T-cells and their anti-tumor effects. 
The treatment was generally well tolerated, and was associated with possible anti-tumor effects in all 
three patients. Similar patient groups not receiving adoptive T-cell therapy generally progress within 
6 months; however, two patients in this study remained progression-free for one and two years 
following treatment. The third patient had a partial remission, but relapsed one year after the T-cell 
transfers. The engineered T-cells were detected in blood up to one year, and no host responses 
against the engineered T-cells were detected. Thus, this pilot study supports recent modifications to 
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CAR design and pretreatment lymphodepletion as promising anti-tumor immuno-therapies. Ongoing 
developments in ex vivo culturing and T-cell modifications, which are aimed at establishing greater 
CAR surface expression, T-cell proliferation and effector function in vivo, are hoped to provide more 
durable anti-tumor T-cell responses in future patients. 
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(a) Schematic of anti-CD20 chimeric antigen 
receptor (CAR). (b) PET-CT scan of a cervical 
lymph node at baseline and 3 months after 
receiving anti-CD20 CAR T-cell infusions, 
showing the clinical response of a B-cell 
lymphoma patient to the new ‘third generation’ 
CD20-specific adoptive immunotherapy. 
